Catalysts / MIRM
Upcoming FDA decisions and readouts we track for Mirum Pharmaceuticals, each with the filing that announced it.
FreeBioList tracks 1 upcoming catalyst for Mirum Pharmaceuticals (MIRM, listed on Nasdaq). It concerns Zilurgisertib (Fibrodysplasia ossificans progressiva (FOP)).
First on the list: the PDUFA date for Zilurgisertib (Fibrodysplasia ossificans progressiva (FOP)), dated 26 Sep 2026, which has passed without an outcome recorded here yet, so check the source and the company's latest filings.
The row links to an SEC filing (8-K or 6-K). It has been verified by a person reading the filing itself, most recently on 11 Sep 2026. The methodology page explains each status.
Background reading: What a PDUFA date is, and why the FDA doesn't publish them.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| Mirum Pharmaceuticals MIRM · Nasdaq | Zilurgisertib | Fibrodysplasia ossificans progressiva (FOP) | 26 Sep 2026 11d ago |
PDUFA date | Verified | 8-K exhibit 99.1 ↗ | Yes |
FreeBioList